| Literature DB >> 33803884 |
Paolo Bevilacqua1, Silvia Nuzzo1, Enza Torino2,3, Gerolama Condorelli4,5, Marco Salvatore1, Anna Maria Grimaldi1.
Abstract
Nanoparticles (NPs) are promising platforms for the development of diagnostic and therapeutic tools. One of the main hurdle to their medical application and translation into the clinic is the fact that they accumulate in the spleen and liver due to opsonization and scavenging by the mononuclear phagocyte system. The "protein corona" controls the fate of NPs in vivo and becomes the interface with cells, influencing their physiological response like cellular uptake and targeting efficiency. For these reasons, the surface properties play a pivotal role in fouling and antifouling behavior of particles. Therefore, surface engineering of the nanocarriers is an extremely important issue for the design of useful diagnostic and therapeutic systems. In recent decades, a huge number of studies have proposed and developed different strategies to improve antifouling features and produce NPs as safe and performing as possible. However, it is not always easy to compare the various approaches and understand their advantages and disadvantages in terms of interaction with biological systems. Here, we propose a systematic study of literature with the aim of summarizing current knowledge on promising antifouling coatings to render NPs more biocompatible and performing for diagnostic and therapeutic purposes. Thirty-nine studies from 2009 were included and investigated. Our findings have shown that two main classes of non-fouling materials (i.e., pegylated and zwitterionic) are associated with NPs and their applications are discussed here highlighting pitfalls and challenges to develop biocompatible tools for diagnostic and therapeutic uses. In conclusion, although the complexity of biofouling strategies and the field is still young, the collective data selected in this review indicate that a careful tuning of surface moieties is a pivotal step to lead NPs through their future clinical applications.Entities:
Keywords: biofouling; diagnosis; drug delivery; nanoparticle; protein corona; therapy
Year: 2021 PMID: 33803884 PMCID: PMC8003124 DOI: 10.3390/nano11030780
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Nanoparticles fate: Scheme of current understanding antifouling mechanisms.
Characteristics of included studies on antifouling nanoparticles (NPs) in diagnostic.
| Author | Year | Nanostructure | Antifouling Moiety | In Vitro Model | In Vivo Model | Application |
|---|---|---|---|---|---|---|
| Cho et al. | 2009 [ | Iron Oxide NPs (TCL-SPION) | poly(3-(trimethoxysilyl)propyl methacrylate-r-PEG methylethermethacrylate-r-N-acryloxysuccinimide) | - | BALB/c mice | Optical imaging (OI) |
| Oh et al. | 2011 [ | Tantalum Oxide | Polyethylen Glycol (PEG) | RAW264.7 | Rats | Bimodal imaging |
| Liu et al. | 2014 [ | Hybrid Lutetium Oxide NPs | PEG | MCF-7 | Kunming mice, C57BL/6 mice, and wister rats | Multimodal imaging |
| Joeng et al. | 2013 [ | Poly (oxyethylene galactaramide)s (PEGA) NPs | PEGA | Hela | SCC7 tumour-bearing mice | OI |
| Li et al. | 2015 [ | Magnetic Iron Oxide NPs | PEG and allyl glycidyl ether (PEG-b-AGE) | RAW264.7, D556, Daoy, U87MG, MDA-MB-231, MCF7 and A549 | - | Theranostic |
| Tu et al. | 2016 [ | Silicon Quantum DotNanoparticles (SiQD-NPs) | PEG and Bovine Serum Albumin (BSA) | CHO, SKOV3 | - | OI |
| Suàrez-Garzìa | 2021 [ | Metal-phenolic NPs (MPS) | PEG | CT26, HeLa, 3T3 | bearing CT26 tumour-bearing mice | SPECT/PET |
| Li et al. | 2019 [ | Gold NPs | L-cysteine-functionalized with poly(but-3-yn-1-yloxy)-2-oxo- | RAW264.7 | - | Theranostic |
| Sui et al. | 2020 [ | Ultrasmall Gadolinium oxide NPs Gd2O3 NPs) | PEG-L-cysteine | RAW264.7 | B16 lung cancer metastasis mouse model | MRI |
| Wang et al. | 2017 [ | Manganese Oxide NPs (Mn3O4NPs) | PEG-L-cysteine | C6 and Raw 264.7 | Mouse | MRI |
| Ma et al. | 2017 [ | Iron Oxide NPs | PEG-L-cysteine | L929 | Rats | MRI |
| Wang et al. | 2019 [ | Mn3O4 NPs | L-lysine | KB | Mouse | MRI |
| Xiong et al. | 2017 [ | Dendrimer-entrapped gold NPs (Au DENPs) | Carboxybetaine Acrylamide (CBAA) | U87MG | U87MG tumour-bearing mice | X-ray CT |
| Liu et al. | 2019 [ | Gadolinium(-Complexed Dendrimer-Entrapped Gold NPs (Gd-Au DEN-PS.) | CBAA, 2-methacryloyloxyethyl phosphorylcholine (MPC) or 1,3-propane sultone (1,3-PS) | Macrophage | B16 lung cancer metastasis mouse model | Bimodal imaging |
| Zhu et al. | 2019 [ | poly(cyclotriphosphazene-co-polyethylenimine) nanospheres (PNSs) | 1,3-PS | 4T1 cells | 4T1 tumor-bearing mouse | Theranostic |
| Ferretti et al. | 2020 [ | IONPs | Zwitterionic Dopamine Sulfonate (ZDS) | BV2 and glial cells | CD-1 mice | MRI |
| Tasso et al. | 2015 [ | Quantum dot | Poly(methacrylamidosulfobetaine-block-4-vinylimidazole) | HEK293 | - | OI |
| Wang et al. | 2014 [ | Superparamagnetic Iron Oxide NPs (SPIO) | BSA | PDAC, Panc-1 | - | MRI |
| Lamanna et al. | 2011 [ | IONPs | Phosphonate | U87MG | Rats | Multimodal imaging (OI and MRI) |
| Cotin et al. | 2019 [ | IONPs | Dendron coating | Huh7 | CD-1 mice | Theranostic |
| Karmali et al. | 2012 [ | SPIO | Crosslinked dextran | - | C57BL/6J mice | MRI |
| Chen et al. | 2013 [ | IONPs | Poly(ethylene oxide)-block-poly(γ-methacryloxypropyltrimethoxysilane) (PEO-b-PγMPS) | SK-BR-3, MDA-MB-231, MCF-7, | 4T1 mice | MRI |
Characteristics of included studies on antifouling NPs in therapy.
| Author | Year | Nanostructure | Antifouling Moiety | In Vitro Model | In Vivo Model | Application |
|---|---|---|---|---|---|---|
| Lv et al. | 2017 [ | Lipidic NPs | polyethylene glycol (PEG) | SKOV-3 | - | Targeted drug delivery |
| Park et al. | 2015 [ | poly(ethyleneimine) (aPEI) NPs | PEG | Hela | SCC7 tumor bearing mice | Drug delivery |
| Yao et al. | 2017 [ | Poly(D,L-lactide-co-glycolide) (PLGA) NPs | PEG-hydrophilic block, hexadecyl hydrophobic block, and a 2-nitrobenzyl linker | HepG2 and | HepG2 tumour-bearing nude Balb/c mice | Drug delivery |
| Elsabahy et al. | 2013 [ | Polyphosphoester (PPE) micelle | Zwitterionic diblock copolymers (acrylic acid/amino group (1:1)) | RAW 264.7 | - | Drug delivery |
| Huang et al. | 2016 [ | Hollow gold-silver nanoshells | Cysteine | MDA-MB-453 | - | Hyperthermia |
| Zheng et al. | 2020 [ | Poly(N-isopropylacrylamide) (PNIPAM) Nanogels | Sulfobetaine methacrylate (SBMA) | L929 and HepG2 | H22-bearing mice | Photothermal drug delivery |
| Ma et al. | 2018 [ | Dendritic carbon dots (CDs) | Poly(carboxybetaine methacrylate) (pCBMA) | 4T1 and HepG2 | BALB/c mice | Drug delivery |
| Xiong et al. | 2019 [ | Dendrimer-entrapped gold NPs (Au DENPs) | Carboxybetaine acrylamide (CBAA) | Hela | - | Gene delivery |
| Ding et al. | 2019 [ | poly(2-(diisopropylamino)ethyl methacrylate) (PDPA)NPs | pCBMA | RAW 264.7, HeLa, and U87 | - | Targeted drug delivery |
| Ellis et al. | 2017 [ | Gold NPs (Au NPs) | Poly(2-(methacryloyloxy)ethyl phosphorylcholine) pMPC | MCF-7 | - | Drug delivery |
| Ding et al. | 2020 [ | Au NPs | Peptide sequence of glutamic acid and lysine | LM3 | LM3 | Radiotherapy |
| Wu et al. | 2017 [ | Au NPs | Peptide sequence of glutamic acid and lysine | SCC-7 | SCC-7 tumour-bearing mice | Photodynamic therapy |
| Wu et al. | 2017 [ | Au NPs | Peptide sequence of glutamic acid and lysine and RGD moieties | A549 | - | Photodynamic therapy |
| Li et al. | 2020 [ | Au DENPs | 1,3-propane sultone (1,3-PS) | RAW264.7 | Collagen-induced arthritis (CIA) mouse | Targeted drug delivery |
| Liu et al. | 2016 [ | Mesoporous Silica NPs | -COO− and -HN+(Me)2 | SCC, HaCaT | - | Theranostic |
| Chen et al. | 2017 [ | poly(10-hydroxy-camptothecin methacrylate (pMPC-b-pHCPT) Micelles | pMPC | HeLa and L929 | Kunming mice and nude mice | Drug delivery |
| Chen et al. | 2019 [ | Cationic gelatin NPs ((+)GNPs) | pMPC | HeLa | SD rats and nude mice | Targeted drug delivery |
| Wang et al. | 2019 [ | Janus dendrimer (JD GPC) | Glycerylphosphorylcholine (GPC) | HT-29, SKOV-3, | BALB/c mice, | Drug delivery |
| Chen et al. | 2014 [ | Crystallized iron NPs (HCIONPs) | Poly(ethylene oxide)-block-poly(γ-methacryloxypropyltrimethoxysilane) (PEO-b-PγMPS) | SUM-159 | SUM-159 tumor-bearing BALB/c mice | Targeted drug delivery |
| Shi et al. | 2018 [ | Silver NPs (Ag NPs) | Chitosan and dextran | NIH 3T3 | SD rats | Targeted drug therapy |
| Huang et al. | 2020 [ | (Etherified starch-coated poly(methyl methacrylate- co-acrylic acid) Micelles | Amphoteric starch | SW480 and A549 | - | Targeted drug therapy |
Figure 2PRISMA flow diagram. From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097, doi:10.1371/journal.pmed1000097. For more information, visit: www.prisma-statement.org.